Klin Padiatr 2013; 225(06): 357-361
DOI: 10.1055/s-0033-1354416
Report
© Georg Thieme Verlag KG Stuttgart · New York

The EuroNet Paediatric Hodgkin Network – Modern Imaging Data Management for Real Time Central Review in Multicentre Trials

Das EuroNet-Paediatric-Hodgkin-Netzwerk – Modernes Bilddatenmanagement innerhalb von multizentrischen Studien mit zentraler Referenzbegutachtung
L. Kurch
1   Department of Nuclear Medicine, University Hospital of Leipzig, Germany
,
C. Mauz-Körholz
2   Department of Paediatrics, Martin-Luther-University Halle/Wittenberg, Halle/Saale, Germany
,
S. Bertling
3   Hermes Medical Solutions, Stockholm, Sweden
,
M. Wallinder
3   Hermes Medical Solutions, Stockholm, Sweden
,
M. Kaminska
1   Department of Nuclear Medicine, University Hospital of Leipzig, Germany
,
D. Marwede
1   Department of Nuclear Medicine, University Hospital of Leipzig, Germany
,
L. Tchavdarova
1   Department of Nuclear Medicine, University Hospital of Leipzig, Germany
,
T. W. Georgi
1   Department of Nuclear Medicine, University Hospital of Leipzig, Germany
,
A. Elsner
3   Hermes Medical Solutions, Stockholm, Sweden
,
A. Barthel
1   Department of Nuclear Medicine, University Hospital of Leipzig, Germany
,
D. Stoevesandt
4   Department of Radiology, Martin-Luther-University Halle/Wittenberg, Halle/Saale, Germany
,
D. Hasenclever
5   Institute for Medical Informatics, Statistics and Epidemiology (IMISE), University of Leipzig, Germany
,
B. Sattler
1   Department of Nuclear Medicine, University Hospital of Leipzig, Germany
,
O. Sabri
1   Department of Nuclear Medicine, University Hospital of Leipzig, Germany
,
D. Körholz
2   Department of Paediatrics, Martin-Luther-University Halle/Wittenberg, Halle/Saale, Germany
,
R. Kluge
1   Department of Nuclear Medicine, University Hospital of Leipzig, Germany
› Author Affiliations
Further Information

Publication History

Publication Date:
28 October 2013 (online)

Abstract

Since 2007, children and adolescents with Hodgkin lymphomas are treated in the Europe-wide EuroNet-PHL trials. A real time central review process for stratification of the patients enhances quality control and efficient therapy management. This process includes reading of all cross-sectional-images. Since reference evaluation is time critical, a fast, easy to handle and safe data transfer is important. In addition, immediate and constant access to all the data has to be guaranteed in case of queries and for regulatory reasons. To meet the mentioned requirements the EuroNet Paediatric Hodgkin Data Network (funded by the European Union – Project Number: 2007108) was established between 2008 and 2011. A respective tailored data protection plan was formulated. The aim of this article is to describe the networks’ mode of operation and the advantages for multi-centre trials that include centralized image review.

Zusammenfassung

Seit 2007 werden Kinder und Jugendlichen, die an einem Hodgkin-Lymphom erkranken innerhalb der europaweit rekrutierenden EuroNet-Studien behandelt. Ein in Echtzeit ablaufender zentraler Referenzprozess zur Stratifizierung der Patienten gewährleistet eine qualitätskontrollierte Behand­lung und ein effizientes Therapiemanagement. Dieser Prozess beinhaltet auch die zentrale Refe­renzbegutachtung der durchgeführten Schnittbildgebungen. Auf­grund der Dringlichkeit ist ein schneller, einfach zu handhabender und sicherer Transport der Bilddaten besonders wichtig. Außerdem muss garantiert sein, dass die Bildgebungen im Fall von Nachfragen ständig verfügbar sind und dass die Datenaufbewahrung den entsprechenden Datenschutzbestimmungen folgt. Um benannte Anforderungen zu erfüllen, wurde im Zeitraum von 2008–2011 das EuroNet-Paediatric-Hodgkin-Datennetzwerk aufgebaut (gefördert von der EU, Projekt-Nr. 2007108). Ein auf das Datennetzwerk zugeschnittener Daten­schutzplan wurde erstellt. Ziel dieses Artikels ist, die Funktionsweise des Netzwerkes mit seinen Vorteilen, speziell für Multizenterstudien, die eine Refe­renzevaluation der Bildgebung vorsehen, zu ­beschreiben.

 
  • References

  • 1 Bhatia S, Yasui Y, Robison LL et al. Late effects study group: High risk of subsequent neoplasm continues with extended follow-up of childhood Hodgkin’s lymphoma: Report from the late effects study group. JCO 2003; 21: 4386-4394
  • 2 Creutzig U, Jürgens H, Herold R et al. Konzepte der GPOH und des Kompetenznetzes zur Weiterentwicklung und Qualitätssicherung in der Pädiatrischen Onkologie. Klin Pädiatr 2004; 216: 379-383
  • 3 Dieckmann K, Pötter R, Wagner W et al. Up-front centralized data review and individualized treatment proposals in a multicenter pediatric Hodgkin’s disease trial with 71 participating hospitals: The experience of the German-Austrian pediatric multicenter trial DAL-HD-90. Radiother Oncol 2002; 62: 191-200
  • 4 Dieckmann K, Pötter R, Hofmann J et al. Does bulky disease at diagnosis influence outcome in childhood Hodgkin’s disease and require higher radiation doses? Results from the German-Austrian pediatric multicenter trial DAL-HD-90. Int J Rad Oncol Biol Phys 2003; 56: 644-652
  • 5 Dörffel W, Albrecht M, Lüders H et al. Multinationale Therapiestudie für den Morbus Hodgkin bei Kindern und Jugendlichen GPOH-HD95. Zwischenbericht nach 2 1/2 Jahren. Klin Padiatr 1998; 210: 212-219
  • 6 Dörffel W, Lüders H, Rühl U et al. Preliminary results of multicenter trial GPOH-HD95 for treatment of Hodgkin’s disease in children and adolescents: Analysis and Outlook. Klin Padiatr 2003; 215: 139-145
  • 7 Dörffel W, Rühl U, Lüders H et al. Treatment of children and adolescents with Hodgkin Lymphoma without radiotherapy for patients in compete remission after chemotherapy: Final results of the multinational trial GPOH-HD95. JCO 2013; 31: 1562-1568
  • 8 Haase R, Vilser C, Mauz-Körholz C et al. Evaluation of the prognostic meaning of C-reactive protein (CRP) in children and adolescents with classical Hodgkin’s lymphoma (HL). Klin Pädiatr 2012; 224: 377-381
  • 9 Hall GW, Katzilakis N, Pinkerton CR et al. Outcome of children with nodular lymphocyte predominant Hodgkin lymphoma – A Children’s Cancer and Leukaemia Group report. British Journal of Haematology 2007; 138: 761-768
  • 10 http://ec.europa.eu/justice/data-protection/law/status-implementation/index_en.htm#h2-5
  • 11 http://europa.eu/legislation_summaries/information_society/data_protection/14012_en.htm
  • 12 Kluge R, Körholz D. Die Bedeutung der FDG-PET für die Stadieneinteilung und Therapie des Hodgkin-Lymphoms im Kindesalter. Klin Padiatr 2012; 223: 315-319
  • 13 Körholz D, Claviez A, Hasenclever D et al. The concept of the GPOH-HD-2003 therapy study for pediatric Hodgkin’s disease: Evolution in the tradition of the DAL/GPOH studies. Klin Padiatr 2004; 216: 150-156
  • 14 Körholz D, Kluge R, Wickmann L et al. Importance of F18-Fluorodeoxy-D-2-Glucose Positron Emission Tomography (FDG-PET) for staging and therapy control of Hodgkin’s lymphoma in childhood and adolescence – Consequences for the GPOH-HD 2003 protocol. Onkologie 2003; 26: 489-493
  • 15 Körholz D. Data security concept for the Clinical Reference Centre of the GPOH-HD study group taking particular account of the tele-radiology platform in the European Paediatric Hodgkin’s Network (EuroNet-PHL-TRP) for the exchange of treatment data and medical imaging data in the context of the EuroNet-PHL study group’s network.
  • 16 Kurch L, Hasenclever D, Elsner A et al. Semiautomatic approach for discrimination between adequate and inadequate early response in FDG-PET/CT of paediatric Hodgkin lymphoma patients. Journal of Nuclear Medicine 2012; 53 (Supplement 1) 155
  • 17 Lüders H. Vergleich der Behandlungsergebnisse der Studien GPOH-HD 95 und HD-Intervall zur Behandlung des Hodgkin Lymphoms im Kindes- und Jugendalter: Bedeutung der zentralen Referenzbegutachtung für die optimale Diagnostik und den Behandlungserfolg. Dissertation an der Martin-Luther-Universität Halle/Saale 2011
  • 18 Mauz-Körholz C, Hasenclever D, Dörffel W et al. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin’s Lymphoma: The GPOH-HD-2002 Study. JCO 2010; 28: 3680-3686
  • 19 Mauz-Körholz C, Gorde-Grosjean S, Hasenclever D et al. Resection alone in 58 children with limited stage Lymphocyte-predominant Hodgkin lymphoma – Experience from the European Network Group on Pediatric Hodgkin lymphoma. Cancer 2007; 110: 179-185
  • 20 Niehues T, Schellong G, Dörffel W et al. Immunodeficiency and Hodgkin’s disease: Treatment and outcome in the DAL HD 78-90 and GPOH-HD95 studies. Klin Padiatr 2003; 215: 315-320
  • 21 Purz S, Mauz-Körholz C, Körholz D et al. [18F] Fluorodeoxyglucose Positron Emission Tomography for detection of bone marrow involvement in children and adolescents with Hodgkin’s lymphoma. JCO 2011; 29: 3523-3528
  • 22 Schellong G. The balance between cure and late effects in childhood Hodgkin’s lymphoma: The experience of the German-Austrian Study Group since 1978. German-Austrian Pediatric Hodgkin’ Disease Study Group. Annals of Oncology 1996; 7 (Supp 4) 67-72
  • 23 Schellong G, Pötter R, Brämsweg J et al. High cure rates and reduced long term toxicity in pediatric Hodgkin’s disease: The German-Austrian Multicenter Trial DAL-HD-90. JCO 1999; 17: 3736-3744
  • 24 Schellong G, Riephausen M, Bruch C et al. Late Valvular and other Cardiac Diseases after different doses of mediastinal radiotherapy for Hodgkin disease in childhood and adolescents: Report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD Studies. Ped Blood Cancer 2010; 55: 1145-1152
  • 25 Spitzer M, Ullrich T, Ueckert F. Securing a web-based teleradiology platform according to German la wand best practices. Stud Health Technol Inform 2009; 150: 730-734
  • 26 Ueckert FK, Prokoschl HU. Implementing Security and Access Control Mechanisms for an electronic healthcare record. Proc AMIA Symp 2002; 825-829
  • 27 Wickmann L, Lüders H, Dörffel W. 18-FDG-PET-Befunde bei Kindern und Jugendlichen mit Morbus Hodgkin: Retrospektive Auswertung zur Korrelation mit anderen bildgebenden Verfahren bei der initialen Stagingdiagnostik und zum prädiktiven Wert bei Verlaufsuntersu­chungen. Klin Padiatr 2003; 215: 146-150